EMA Gives Nod To Bydureon, Approves Additional Indication For Pradaxa

The CHMP has recommended Bydureon for authorization, despite reservations having been expressed by FDA. An additional indication for Pradaxa was also recommended, boosting the drug's profile as a potential blockbuster.